Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy
Study Overview
This phase III trial compares nephrectomy (surgery to remove a kidney or part of a kidney) with nivolumab to the usual approach of nephrectomy followed by standard post-operative follow-up and monitoring, in treating patients with kidney cancer that is limited to a certain part of the body (localized). Nivolumab is a drug that may help stimulate the immune system to attack any cancer cells that may remain after surgery. The addition of nivolumab to the usual surgery could prevent the cancer from returning. It is not yet known whether nivolumab and nephrectomy is more effective than nephrectomy alone in treating patients with kidney cancer.
Study Description
A Phase 3 Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
- ClinicalTrials.gov Identifier: NCT03055013
- Protocol Number: 17-704
- Principal Investigator: David McDermott
Recruitment Status
OpenContact the research team to learn more about this study.
Fields marked with asterisk (*) are required